Inhibin B – Evaluation of laboratory reference values in children and adolescents as well as a statement to validity and clinical appliance in pediatric diabetology and pediatric cancer survivors
- Conditions
- study for standard/normal valuesE10.90E89.9Follow-up examination after unspecified treatment for malignant neoplasmZ08.9Postprocedural endocrine and metabolic disorder, unspecified
- Registration Number
- DRKS00015263
- Lead Sponsor
- KKJM, UK FfM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
including criteras:
• informed consent
• Aged < 20 years
• no other relevant disease
• patients with Diabetes mellitus
• patients after cancer therapy, as well as after stem cell transplantation
Exclusion Criteria
excluding criterias:
• aged = 20 years at start of study
• acute disease
• other chronic disease (HIV, Tbc)
• pregnancy
• substance abuse
• parents beeing unable to understand the subject of the study
• participation in another AMG study
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In this study standard values for Inhibin B will be described as well as an interpretation will be given for Inhibin B in chronic health conditions of pediatric patients with diabetes mellitus and in young survivors of childhood cancer disease. The newly developed Assay „Inhibin B Gen II ELISA may differentiate between structural subgroups of Inhibin B and perform a more accurate measurement since before. <br>
- Secondary Outcome Measures
Name Time Method